Ranjit Shahani

Budget is very strategic, it is obviously work in progress, and the nine pillars which the finance minister mentioned are great, says Ranjit Shahani, vice-chairman and managing director Novartis India

India needs predictable IPR regime: Novartis

Novartis India, Managing Director and Vice Chairman, Ranjit Shahani says they want to go from Make in India to invent in India because any economy which needs to be successful, the core has to be innovation.

Change policies annually, not on ad hoc basis: Novartis

Speaking exclusively to CNBC TV18's Priya Sheth, Managing Director and Vice Chairman of Novartis Ranjit Shahani says that if the government needs to make a change in policy then it should be done on an annual basis

Novartis gets USFDA nod for heart failure drug

Novartis India Country President Ranjit Shahani said the early approval by the USFDA, ahead of priority review date of LCZ696, will benefit many patients afflicted with heart failure.

From Apple to Novartis: Why some patents deserve to die

Yesterday's Supreme Court judgment in the case of Novartis‘ anti-cancer drug Glivec has given rise to calls for stronger patent protection in India. The multinational lobby is yelling blue murder, and Novartis India‘s chief Ranjit Shahani has muttered darkly about how "the intellectual property ecosystem in India is not very encouraging."

Novartis: Will continue investing in India, but cautiously

Novartis India on Monday said it is disappointed with the Supreme Court verdict rejecting its patent plea for blockbuster cancer drug Glivec. It will continue to invest in India, but cautiously, Ranjit Shahani, vice-chairman and MD of Novartis India told reporters in Mumbai.

Analysts see no big impact of pricing policy on pharma cos

A new pricing policy finalised by a ministers panel on Thursday, which will bring 348 essential drugs under government price control, is unlikely to have a major impact on the earnings of pharmaceutical companies, according to analysts.

Budget Expectations: Pharma Producers body calls for infra status to healthcare

As 16 March draws close, Indian healthcare is once again at the crossroads waiting with bated breath for the Union Budget in the hope that it will provide the necessary impetus to the pharmaceutical industry. Announcing Infrastructure status for Healthcare would be just what the doctor ordered.

Pharma industry fragmented, see more consolidation: Expert

In an interview with CNBC-TV18’s Menaka Doshi, Ranjit Shahani, President, Organisation of Pharmaceutical Producers of India and Chairman, Novartis, discusses the outlook for the pharma sector both from the M&A point of view as well as the FDI cap point of view.